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Overview of Process 
During the past 12 months, the Division of STD Prevention (DSTDP) Senior Staff led the 
Division’s strategic planning process to produce this five-year strategic plan meant to guide 
DSTDP’s decision making, human and financial resource allocation, and programmatic 
direction.  The process included collaboration across DSTDP through its six branches, with its 
six cross-disciplinary workgroups, and with units within the Office of the Director.  In addition, 
selected external colleagues were asked in structured interviews to react to draft goals and 
objectives, and senior staff from National Center for HIV/AIDS, Viral Hepatitis, STD and TB 
Prevention (NCHHSTP) reviewed the final draft.  Comments, suggestions, concerns and 
questions from all of these contributors were taken into account in finalizing this plan.  DSTDP 
underwent a comprehensive external review of its research portfolio in October of 2007, and the 
report from this review also informed the strategic planning process.  Previous DSTDP Strategic 
Plans from 1995 and 2000 provided useful platforms for development of this plan. Throughout 
the process, DSTDP benefitted from the outside advice and facilitation of consultants Harry 
Chambers and Becky Setliff of DB Consulting.   
 
Completion of the plan ends only the first phase of the process.  The plan is meant to be a living 
document, used regularly by DSTDP decision makers to prioritize work and evaluate 
opportunities as they arise.  DSTDP intends to incorporate regular review of the utility of the 
objectives and strategies to assure the document remains both a current roadmap for the future, 
as well as a useful guide for key management decisions.  It is purposely short and focused to 
optimize regular use and review. While the goals, objectives, and strategies outlined in the plan 
are not intended to comprehensively cover all current and future divisional activities, they do 
indicate the priority areas on which the division will focus the majority of its resources. 
 
Context 
Sexually transmitted diseases (STDs) remain a major public health challenge in the United 
States. While substantial progress has been made in preventing, diagnosing, and treating certain 
STDs in recent years, CDC estimates that approximately 19 million new infections occur each 
year, almost half of them among young people ages 15 to 24. In addition to the physical and 
psychological consequences of STDs, these diseases exact a tremendous economic toll. Direct 
medical costs associated with STDs in the United States are estimated at up to $15.3 billion 
annually in 2007 dollars.  STDs are also health outcomes for which the greatest disparities exist. 
Contributing to the magnitude of these disparities may be the fact that racial and ethnic 
minorities are more likely to seek care in public health clinics, and these clinics report STDs 
more completely than private providers. However, this reporting bias does not explain these 
differences. Another contributing factor is higher prevalence of disease in these populations, 
perhaps attributable to societal factors such as limited access to quality health care, poverty, 
higher incarceration rates, unequal educational access and achievement, high unemployment 
rates, and racism.  The DSTDP Strategic Plan was developed in the context of these social 
realities; the current condition of the nation’s inadequate public health infrastructure at the 
federal, state and local levels; and current scientific knowledge and program focus.   
It is important to note the hierarchical relationship of the Division within CDC, CCID and 
NCHHSTP.  Appendix A contains a table summarizing the relationship of the DSTDP goals and 
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objectives to CDC, CCID and NCHHSTP goals. In addition, much work relevant to STD 
prevention is conducted through other divisions at CDC (e.g., primary prevention/youth 
education—DHAP, DASH; viral hepatitis prevention—DVH; immunization programs—
NCIRD; pregnancy prevention—DRH, DASH) which broadly complements the STD prevention 
efforts of DSTDP outlined in this plan.  Of equal importance is the reality that most STD 
prevention activities occur in communities, involving multiple and varied contributors whose 
activities reflect local priorities, capacities, and resources which may be only marginally or 
indirectly affected by DSTDP.  
 
Mission 
DSTDP’s mission is to provide national leadership, research, policy development, and 
scientific information to help people live safer, healthier lives by the prevention of STDs and 
their complications.  This mission is accomplished by assisting health departments, healthcare 
providers and non-government organizations (NGOs) through the provision of timely science-
based information and by clearly interpreting such information to the general public and policy 
makers.  The Division’s specific disease prevention goals are contextualized within the broader 
frameworks of the social determinants of health, the promotion of sexual health, and the primary 
prevention of sexually transmitted infections.   
 
Guiding Principles 
Additional context for both the process of creating the strategic plan and its content are core 
organizational values that guide our everyday work and actions:  
 
• Because we value our staff, we will 
￭ Provide professional challenge and professional opportunities for growth 
￭ Provide clear roles and responsibilities 
￭ Emphasize equity in our decisions 
￭ Delegate to appropriate levels 
￭ Respect diverse opinions 
 
• Because we value scientific expertise, we will 
￭ Base decisions, information, and guidance on scientific evidence 
￭ Encourage critical thinking, innovation, constructive questioning, initiative, and 
excellence 
￭ Mentor new scientists and public health professionals 
￭ Promote robust interaction among program, science, and policy 
 
• Because we value collaboration and science/program integration, we will 
￭ Create a work environment that encourages collaborative critical thinking and 
excellence  
￭ Endeavor to translate science-based knowledge to program practice 
￭ Develop and support teamwork 
￭ Catalog and support crosscutting initiatives 
￭ Support/respect local authority 




• Because we value accountability and seek to maximize public health benefit, we will 
￭ Favor decisions that call for actions that improve public health 
￭ Foster efficient and effective program surveillance, research, and policy 
￭ Hold ourselves accountable to all whom we serve at all levels 
￭ Practice open, transparent decision making 
￭ Seek out and implement ways to reduce redundant processes 
￭ Continuously review our operational processes 
￭ Identify gaps and develop appropriate solutions  
 
Organization of Strategic Plan 
DSTDP’s Strategic Plan is organized around seven goals, with supporting objectives and 
strategies for each.  While the plan captures the goals, objectives and strategies, in the process of 
developing the strategic plan, many existing and potential new activities were identified and 
discussed.  These activities provide further specificity and begin to outline the work of the 
division.  The work of the Division in the first several months of implementation, and regularly 
throughout the next five years, will be to identify and develop new activities to support the 
strategies, as well as to support existing activities which serve these purposes.     
 
Seven Strategic Goals 
 
• Prevent STI-related infertility 
• Prevent STI-related adverse outcomes of pregnancy 
• Prevent STI-related cancers 
• Prevent STI-related HIV transmission 
• Strengthen STD prevention capacity and infrastructure 
• Reduce STD health disparities across and within communities and populations 
• Address the effects of the social and economic determinants and the costs of specific 
STDs and associated sequelae among specific populations 
 
The objectives and strategies that will be pursued to achieve the goals are specified in the table 
on the following pages.   
 
Implementation of the Strategic Plan 
 To serve DSTDP well, the plan will be used to: 
• Organize and structure our work 
• Communicate DSTDP priorities within the division, across CDC, and to external partners 
• Guide management decisions about research and program agendas and human and 
financial resource allocation 
• Ensure alignment with NCHHSTP and CDC goals and direction 
• Provide a platform for collaboration across CDC and with external partners 
 The plan will be reviewed regularly to ensure it continues to reflect appropriate priorities in the 
context of a changing environment.  DSTDP will evaluate the effectiveness of the strategies and 
activities in meeting the objectives and will make necessary changes to reflect completion of 
work, revision of work to incorporate new knowledge, and inclusion of new opportunities that 
can contribute to further progress on meeting the objectives.    
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Overview of Goals and Objectives  
 
1. Prevent STI-related infertility 
a. Increase CT screening in women 
b. Decrease CT prevalence in men 
c. Reduce GC incidence 
d. Monitor/respond to multi-drug-resistant GC 
e. Reduce PID 
 
2. Prevent adverse outcomes of pregnancy 
a. Reduce congenital syphilis in the U.S. 
b. Support global congenital syphilis elimination 
c. Reduce sequelae of neonatal herpes 
 
3. Prevent STI-related cancers 
a. Enhance impact of HPV vaccine 
b. Increase use of HBV vaccine in STD clinics 
 
4. Prevent STI-related HIV transmission and acquisition 
a. Reduce domestic HSV-associated HIV transmission 
b. Reduce new HIV infections in international settings 
c. Reduce adult syphilis 
d. Increase HIV screening and associated prevention services in STD clinics 
e. Increase STD screening and associated prevention services in HIV care settings 
 
5. Strengthen STD prevention capacity and infrastructure 
a. Improve prevention impact 
b. Provide training 
c. Leverage partnerships 
d. Improve CDC systems and capacity 
 
6. Reduce STD health disparities 
a. Produce comprehensive DSTDP framework 
b. Reduce syphilis in MSM 
c. Reduce GC in African Americans 
 
7. Address effects of social and economic determinants and costs of STDs and 
associated sequelae among specific populations 
a. Characterize effects of determinants and costs 
b. Develop capacity to address determinants 
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 Goals, Objectives, and Strategies 
 
Goals and Objectives        Strategies 
Goal 1:  Prevent STI-related infertility 
 
 
Prevent STI-related infertility due to Chlamydia  
Objective 1a:  Increase CT screening among women 
under 26 years of age by 30 % from 2007 to 2012 as 
demonstrated by 
• HEDIS CT screening data  
1. Develop provider-specific interventions and resources to normalize chlamydia screening of 
sexually active women < 26 and increase provider provision and initiation of chlamydia 
screening and treatment in private and public healthcare settings. 
2. Expand targeted screening of at-risk female populations (e.g., correctional populations) 
3. Develop approaches to monitor chlamydia incidence and prevalence at the local, state, and/or 
national level.  [Note:  Activities under this strategy will include assessment of existing data 
systems that could be used to estimate incidence in selected communities or populations.] 
4. Increase patient demand for chlamydia screening (e.g., efforts to increase awareness, health 
communication and social marketing campaigns, development of educational materials, 
developing and expanding partnerships).   
5. Develop dynamic mathematical models of chlamydia transmission that can be used to 
evaluate the expected impact of a variety of prevention strategies on chlamydia incidence and 
prevalence.   
6. Develop evaluation approaches to assess community-level impact of CT screening on 
sequelae. 
7. Assess, improve, develop and evaluate data to monitor and inform strategies and activities to 
increase CT screening, including performance measures, surveillance and evaluation data 
(e.g., in particular screening coverage and proportion of infections identified). 
Objective 1b:  Decrease national prevalence of CT in 
men by 30% by from 2005 – 2006 to 2011-2012 as 
demonstrated by: 
• NHANES prevalence data for CT in men 
1. Evaluate public health role of targeted male screening. 
2. Increase the number of jurisdictions where the legal status of EPT is clear. 
3. Increase use of EPT by health care providers in those jurisdictions where EPT is legal. 
4. Assess, improve, develop and evaluate data to monitor and inform strategies and activities to 




Prevent STI-related infertility due to gonorrhea   
Objective 1c:  Reduce GC incidence as demonstrated 
by 
• A decrease in GC among 15 – 44 year old 
women to < 276 per 100,000  by 2010 
1. Develop a programmatic approach to optimize diagnosis, treatment, and control of GC.  
2. Increase GC screening and treatment among targeted populations. 
3. Improve accessibility and acceptability of STD care for males, particularly symptomatic 
males from populations bearing increased burden of gonorrhea in areas with high gonorrhea 
rates. 
4. Expand effective partner services for persons diagnosed with GC. 
5. Assess, enhance, develop and evaluate data to monitor and inform strategies and activities to 
reduce GC incidence, including performance measures, surveillance and evaluation data. 
Objective 1d:  Monitor and respond to increases in 
multi-drug resistant GC as demonstrated by 
• Strengthened domestic and international 
surveillance systems  
 
 
1. Maintain and enhance domestic surveillance systems to monitor and respond to 
cephalosporin-resistant GC. 
2. Collaborate with partners (e.g., WHO, DoD) to enhance global surveillance and reporting 
systems and responses to drug-resistant GC. 
3. Develop a plan to identify and effectively respond to the presence of cephalosporin-resistant 
GC in the U.S. 
4. Develop, evaluate and improve molecular assays for drug resistant gonorrhea to advance 
gonorrhea resistance testing at local reference laboratories domestically and internationally. 
5. Enhance capacity of domestic and international laboratories to support detection and 
containment of cephalosporin-resistant GC to inform domestic and international STI 
treatment guidelines. 
6. Collaborate with partners (e.g., NIH, FDA, industry) to identify and support development of 
effective and appropriate treatment for cephalosporin-resistant GC. 
Reduce PID  
Objective 1e: Reduce PID as demonstrated by  





1. Improve surveillance of serious adverse outcomes associated with CT/GC as determined by 
completion of a monitoring plan by mid-year 2009 and implementation of plan by end of 
year 2010 
2. Clarify genetic factors and the immunologic processes associated with (repeat) chlamydia 
infection and with PID.  




Goal 2:   Prevent STI-related adverse outcomes of 
pregnancy 
 
Objective 2a:  Reduce congenital syphilis in U.S. as 
demonstrated by  
• <8.5 per 100,000 live births by 2010 as 
measured  by morbidity data reported to 
CDC and published in the STD Surveillance 
Report 
1. Expand screening and treatment of pregnant women, particularly at-risk women in areas with 
elevated female or CS cases. 
2. Reduce P&S syphilis among women of child-bearing age through heightened prevention and 
control activities (e.g., access to screening and treatment, patient and provider education, 
partner services) in high prevalence areas  
3. Promote access to prenatal care  
4. Improve congenital syphilis surveillance 
5. Develop, evaluate and improve syphilis diagnostics 
Objective 2b: Develop and support implementation 
of a comprehensive plan for monitoring, evaluation 
and surveillance for the global elimination of 
congenital syphilis as a public health problem.  
 
 
1. With global partners, by 2011, conduct operational research studies that identify effective 
and feasible program progress and impact measures for the global elimination of congenital 
syphilis. 
2. With global partners, by 2013, develop and support implementation of surveillance and 
reporting systems for national, regional and global monitoring, evaluation and surveillance in 
order to measure progress toward the global elimination of syphilis. 
3. By 2013, develop, evaluate and improve syphilis diagnostics to allow prompt identification 
and treatment of syphilis infected women in resource-constrained settings. 
4. By 2013, identify model international programs for service integration in the perinatal and 
post-partum period to promote healthy mothers and babies. 
Objective 2c:  Reduce sequelae associated with 
neonatal herpes by developing, assessing and 
disseminating strategies to enhance prevention, early 
diagnosis, and treatment among pregnant women 
and their babies 
1. Develop approaches to monitor occurrence, track burden of disease associated with, and 
better define epidemiology of neonatal herpes  
2. Develop, assess and disseminate strategies to reduce time to diagnosis and treatment of 
neonatal herpes 
3. Increase provider awareness concerning and index of suspicion regarding neonatal herpes 
Goal 3:  Prevent STI-related cancers  
Objective 3a:  Enhance impact of HPV vaccines by 
monitoring impact and evaluating biologic 
parameters affecting use  
 
1. Monitor vaccine impact on HPV related outcomes, including monitoring prevalence of HPV 
infection, genital warts, and cervical cancer precursors. 
2. Support development of HPV vaccine recommendations in the U.S. 
3. Support implementation of vaccine in U.S. through assessment of biologic parameters and 
other factors that could affect use of the vaccine. 
4. Support international introduction of HPV vaccines and evaluation of their impact. 
Objective 3b:  Increase use of HBV vaccine among 
adults at-risk for HBV infection as demonstrated by 
• An increase of 10% between 2007 and 2010 
in the quantity of 317-funded HBV vaccine 
administered in  STD clinics  
1. Collaborate with other CDC divisions (e.g., ISD and DVH) to implement and evaluate the 
Adult Hepatitis B vaccine initiative in STD clinics. 
2. Promote use of HBV vaccine among MSM. 
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Goal 4:  Prevent STI-related HIV transmission 
and acquisition 
 
Objective 4a:  Reduce HSV-associated HIV 
transmission through 
• Primary prevention of HSV as an HIV 
prevention strategy 
• Preventing HIV among HSV-infected 
persons 
1. Define potential primary HSV prevention strategies based on use of valacylovir suppressive 
therapy in HSV-infected persons. 
2. Define potential primary HSV prevention opportunities based on impact of knowledge of 
serostatus on sexual behavior. 
3. Identify and promote approaches to prevent HIV acquisition among HSV-2-infected persons. 
4. Evaluate and improve diagnosis of HSV through addressing performance of HSV serologic 
tests. 
Objective 4b: Reduce new HIV infections in 
international settings through use of integrated 
HIV/STD approaches 
1. With USG, international, and local partners, develop and enhance STD screening among 
HIV-infected persons. 
2. With USG, international, and local partners, develop and enhance strategies that increase 
HIV testing among STD-infected persons.  
3. With USG, international, and local partners, develop and enhance behavior change and other 
HIV prevention strategies among STD-infected persons.   
4. With USG, international, and local partners, develop and enhance primary HIV/STD 
prevention strategies in persons at high risk for HIV. 
Objective 4c:  Reduce P&S syphilis as determined 
by a reduction in reported syphilis rates by 2010 to: 
• < 0.9 per 100,000 population in women 
• < 5.4 per 100,000 population in men  
1. Assess, enhance, develop, and evaluate data to monitor and inform strategies to reduce P&S 
syphilis in targeted populations, including performance measures, surveillance and 
evaluation data. 
2. Increase access to syphilis treatment and screening services early in disease course. 
3. Develop and leverage media and other partnerships to increase demand for STD testing and 
treatment among targeted populations. 
4. Develop, evaluate and improve syphilis diagnostics for U.S. settings. 
Objective 4d:  By 2013, increase to 80% the number 
of CSPS grantees providing opt-out HIV testing in 
90% of the STD clinics in their jurisdictions 
 
1. Collaborate with other CDC divisions (e.g., DHAP) to implement and evaluate routine HIV 
testing in STD clinics. 
2. Develop approaches (e.g., performance measure, quality of care standards) to support and 
measure implementation of opt-out HIV testing in STD clinics. 
Objective 4e:  Increase adherence to recommended 
STD screening among HIV+ persons as determined 
by syphilis screening among persons attending Ryan 
White Care Act-funded HIV care settings 
 
1. Collaborate with relevant partners to conduct research to develop feasible, acceptable and 
cost-effective models for STD screening in HIV care settings.  
2. Develop, evaluate, and improve STD diagnostics for use in HIV care settings (e.g., 
rectal/pharyngeal testing) and collaborate with relevant partners to promote their use.  
3. Collaborate with HRSA HIV/AIDS Bureau to develop and implement tools to ensure that 
Ryan White grantees routinely screen HIV+ persons in care for STDs. 
4. Assess, enhance, develop and evaluate data to inform strategies and activities in target 
populations, including performance measures, surveillance and evaluation data. 
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Goal 5:  Strengthen STD prevention capacity and 
infrastructure 
 
Objective 5a:  Support the ability of CDC-funded 
STD prevention programs to improve STD 
prevention impact and efficiency  
 
1. Assess, enhance, develop, and evaluate data to monitor and inform strategies and activities to 
support STD prevention programs including performance measures, surveillance and 
evaluation data. 
2. Develop approaches to enhance operational efficiency by STD programs (e.g., leadership 
development, promulgation of best practices, enhancing TA). 
3. Develop and disseminate most current information on prevention strategies, treatment 
recommendations, and program operations (e.g., guidelines and other tools). 
4. Increase and improve research translation activities that can be implemented in STD 
prevention programs. 
5. Provide program evaluation tools and training to Project Areas to support program evaluation 
and improvement.  
6. Continue development and use of Performance Measures system to enhance program 
performance. 
Objective 5b:  Develop and implement sustainable 
strategies to provide training to improve STD 
prevention program capacity   
 
 
1. Provide self-directed and widely available STD program data access, management, and 
analysis courses (including program evaluation).  
2. Develop and deliver training in STD program management for program management staff.  
3. Develop, revise, and deliver training on new and revised clinical, surveillance, and 
programmatic guidance and recommendations. 
4. Develop and deliver training on use of innovative technologies in STD programs. 
5. Develop approaches to ensure that STD prevention program staff receive adequate assistance 
from their programs both before and after they complete training courses. 
6. Periodically assess STD program staff's training needs and evaluate impact of DSTDP-
funded training to improve training effectiveness. 
Objective 5c:  Develop and leverage partnerships to 




1. Develop and implement a strategic roadmap for an appropriate mix of sustainable 
partnerships with organizations external to CDC to support division priorities  
2. Develop and implement approaches to enhance program collaboration and service integration 
with other programs, divisions and centers at CDC  (e.g., integrate recommendations and 
guidance for program activities, use of internet for STD prevention and control; partner 
notification guidelines) 
3. Maintain robust and innovative partnerships with organizations dedicated to STD prevention 
4. Provide leadership to maximize collaboration with other federal agencies to support division 
priorities and enhance public health impact 
5. Enhance partnerships with international organizations to further global STD prevention 
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Objective 5d:  Improve DSTDP systems and 




1. Improve administrative processes by end of FY 2009, as demonstrated by the development of 
a plan for each of the top five management/administrative activities and subsequent 
implementation of the plan.  
2. Develop a staffing plan for field staff and headquarters personnel to identify staffing needs 
(numbers of staff in specific organization units by skill set, KSAs for specific jobs) as 
determined by completion of the plan by end of FY 2008.  
3. Prioritize and implement recommendations from FY 2008 DSTDP OPM Human Capital 
Assessment.  
4. Improve availability, access and usability of data and datasets for STD programs and the 
general public.  
5. Improve DSTDP staff understanding of DSTDP data collections content and characteristics. 
6. Develop open, collaborative approaches and systems to support effective programmatic 
research and surveillance during project planning, initiation and operations within DSTDP. 
7. Develop and implement policy initiatives that support division priorities. 
8. Develop and disseminate health information to support division priorities, ensuring optimal 
use of web and other innovative and interactive technologies.  
9. Develop and implement a strategic communication plan to support division priorities. 
Goal 6:  Reduce STD health disparities across 
(within) communities and populations 
 
Objective 6a:  By end of 2009, produce a 
comprehensive DSTDP framework for reducing 
STD disparities  
 
 
1. Develop measures to evaluate health disparities for STDs. 
2. Develop new programs, guidelines, tools, and evaluation approaches to strengthen prevention 
capacity to reduce health disparities and provide technical assistance on their application. 
3. Develop collaborative partnerships with key internal and external stakeholders to expand 
access to health education and care to promote sexual health. 
4. In partnership with affected community stakeholders and health care providers, conduct 
cross-NCHHSTP and cross CDC joint awareness/health communication activities (e.g., STD 
Awareness Month, World Aids Day and TB Day) on STD prevention initiatives.  
5. Develop and provide training on topics relevant to reducing health disparities.  
Objective 6b:  By 2013 achieve a reduction in P&S 
syphilis incidence among MSM by 15%, as 
determined by the national STD surveillance data  
1. Improve syphilis monitoring and quality of surveillance data. 
2. Improve evidence-based use of prevention strategies (e.g., screening, partner services, public 
and provider awareness) among MSM. 
3. Improve community awareness of symptom recognition, diagnosis and healthcare seeking. 
4. Increase proportion of MSM with syphilis that are diagnosed and treated in the primary 
stage. 
5. Develop, evaluate and improve syphilis diagnostics. 
6. Evaluate use of syphilis rapid tests, when licensed, in settings where MSM can be accessed. 
7. Evaluate and improve partner services for MSM.  
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Objective 6c:  Between 2007 and 2013 reduce GC 
rate among AA by 10% as determined by national 
STD surveillance data.  
 
 
1. Improve community awareness and understanding of gonorrhea and the associated racial 
disparity. 
2. Provide updated guidance on gonorrhea control strategies likely to be effective, cost-
effective, and acceptable to African-American communities.  
3. Develop approaches to enhance access of African-American populations to acceptable and 
high-quality treatment of gonorrhea.  
Goal 7:  Address the effects of the social and 
economic determinants and the costs of specific 
STDs and associated sequelae among specific 
populations 
 
Objective 7a:  By 2009 develop a framework for 
describing and understanding the effects of social 
and economic determinants and costs of specific 
STD among specific populations 
 
1. Develop an approach to assess costs of STDs by specific STD and specific populations and 
disseminate the results. 
2. Perform comprehensive assessment of impact of critical social and economic determinants 
on STDs. 
3. Identify points of intervention to reduce effects of social and economic determinants on STD 
and disseminate findings in a published report by 2009.  
 Objective 7b:  By 2013, incorporate structural 
interventions to address the effects of social and 
economic determinants on STD into STD prevention 
approaches. 
1. Collaborate with relevant partners within and external to CDC to develop and assess 
interventions that address social and economic determinants. 
2. Develop methods for addressing legacies of social and economic discrimination and stigma 
related to STD. 
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Appendix A:  DSTDP Strategic Plan Map to Organizational Goals 
 
DSTDP Goals/Objectives CDC Goals CCID FY 2009 Priorities NCHHSTP Program Imperatives 
1. Prevent STI-related infertility 
a. Increase female CT screening  
b. Decrease male prevalence 
c. Reduce GC incidence 
d. Monitor/respond to multi-drug resistant GC 
e. Prevent PID 
Healthy People in every stage of life   
 Adolescents.  Objectives 17, 18, 20 
 Adults.  Objectives 24, 25, 26, 28, 30 
People prepared for health threats.  
 Objectives 66, 67, 68, 69, 70  
Healthy People in a healthy world 
 Objectives 71, 76 
Expand capacity in pathogen discovery; improve 
infectious disease monitoring, detection, 
preparedness and outbreak response. 
Increase global capacity for preventing and 
controlling infectious diseases and the 
emergence of resistance to all types of anti-
infective agents. 
Reducing health disparities 
Maximizing global synergies 
2. Prevent STI-related adverse outcomes of pregnancy 
a. Reduce congenital syphilis in the U.S. 
b. Support global congenital syphilis elimination 
c. Reduce sequelae of neonatal herpes 
Healthy People in every stage of life   
 Infants.  Objectives 1, 5 
 Adults.  Objectives 24, 25, 26, 28, 30 
Healthy People in a healthy world 
 Objectives 71, 72, 77, 78, 79 
 Reducing health disparities 
Maximizing global synergies 
3. Prevent STI-related cancers 
a. Enhance impact of HPV vaccine 
b. Increase use of HBV vaccine in STD clinics 
Healthy People in every stage of life   
Adolescents.  Objectives 17, 20  
 Adults.  Objectives 25, 26, 27, 28, 30 
Implement new vaccines and new vaccine 
recommendations. 
Eliminate acute HBV transmission in the U.S. 
Program collaboration and 
service integration 
Maximizing global synergies 
4. Prevent STI-related HIV transmission 
a. Reduce domestic HSV-associated HIV 
transmission 
b. Reduce new HIV infections in international 
settings 
c. Reduce adult syphilis 
d. Increase HIV screening and associated prevention 
services in STD clinics 
e. Increase STD screening and associated 
prevention services in HIV clinics 
Healthy People in every stage of life   
 Adults.  Objectives 24, 25, 26, 28, 30 
 Older adults.  Objectives 31, 32, 35, 37 
Healthy People in a healthy world 
 Objectives 71, 78 
 Reducing health disparities 
Maximizing global synergies 
Program collaboration and 
service integration 
5. Strengthen STD prevention capacity and 
infrastructure 
a. Improve prevention impact 
b. Provide training 
c. Leverage partnerships 
d. Improve CDC systems and capacity 
CDC’s strategic imperatives in support of 
the health goals  
Expand disease prevention and control 
strategies through ecologic approach to 
infectious diseases. 
Improve the quality and safety of the healthcare 
system. 
Program collaboration and 
service integration 
6. Reduce health disparities 
a. Produce comprehensive DSTDP framework 
b. Reduce syphilis in MSM 
c. Reduce GC in African Americans 
Healthy People in every stage of life   
 Adolescents.  Objectives 17, 18, 20 
 Adults.  Objectives 24, 25, 26, 28, 30 
 Older adults.  Objectives 31, 32, 35, 37 
Reduce health disparities for all infectious 
diseases, especially HIV, viral hepatitis, STDs 
and TB. 
Reducing health disparities 
Program collaboration and 
service integration 
7. Address effects of social/economic determinants 
and costs of STDs and associated sequelae among 
specific populations 
a. Characterize effects of determinants and costs 
b. Develop capacity to address determinants 
Healthy People in every stage of life   
 Adolescents.  Objectives 17, 18, 20 
 Adults.  Objectives 24, 25, 26, 28, 30 
 Older adults.  Objectives 31, 32, 35, 37 
Reduce health disparities for all infectious 
diseases, especially HIV, viral hepatitis, STDs 
and TB. 
Reducing health disparities 
Program collaboration and 
service integration 
 
